Table 1 Baseline characteristics of the study Population.
COPD | non-COPD | ||||
|---|---|---|---|---|---|
(n = 39) | (n = 68) | p | |||
Age, years | 0.0068** | ||||
Median | 73 | 69 | |||
Range | 52−89 | 38−87 | |||
Sex, n (%) | <0.0001* | ||||
Male | 33 | − 84.6 | 31 | − 45.6 | |
Female | 6 | − 15.4 | 37 | − 54.4 | |
Smoking status, n (%) | 0.0023* | ||||
Current or ex-smoker | 34 | − 87.2 | 40 | − 58.8 | |
Non-smoker | 5 | − 12.8 | 28 | − 41.2 | |
Spirometry | |||||
% FEV1/FVC | 63.9 ± 4.9 | 79.6 ± 5.4 | <0.001** | ||
FEV1 (% of the predicted value) | 81.8 ± 13.6 | 99.0 ± 17.7 | <0.001** | ||
Histology, n (%) | 0.2939* | ||||
Adenocarcinoma | 23 | − 66.7 | 50 | − 73.5 | |
Squamous cell carcinoma | 13 | − 23.3 | 15 | − 22.1 | |
Others | 3 | − 10 | 3 | − 4.4 | |
Stage (UICC-8th edition), n (%) | 0.2210* | ||||
I | 18 | − 46.1 | 44 | − 64.7 | |
II | 14 | − 35.9 | 13 | − 19.1 | |
III | 6 | − 15.4 | 10 | − 14.7 | |
IV | 1 | − 2.6 | 1 | − 1.5 | |
Drugs administered, n (%) | |||||
Inhaled bronchodilator | 24 | − 61.5 | 6 | − 8.8 | <0.0001* |
Inhaled steroids | 4 | − 10.3 | 0 | 0 | 0.0159* |
Oral steroids | 1 | − 2.6 | 2 | − 2.9 | 1.0000* |
Adjuvant therapies | |||||
Radiotherapy | 0 | 0 | 1 | − 1.5 | 1.0000* |
Chemotherapy | 3 | − 7.7 | 16 | − 23.5 | 0.0635* |
CDDP+VNR | 1 | − 2.6 | 5 | − 7.4 | |
CBDCA+S-1 | 0 | 0 | 1 | − 1.5 | |
UFT | 2 | − 5.1 | 10 | − 14.7 | |
Interstitial Lung Disease | 1.0000* | ||||
Yes | 9 | − 23.1 | 15 | − 22.1 | |
No | 30 | − 76.9 | 53 | − 77.9 | |